Navigation Links
Bionovo to Present at the Cambria Capital Investor Meeting

EMERYVILLE, Calif., March 26 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a leader in the discovery and development of safe and effective drugs in the areas of women's health and cancer, is scheduled to present at the Cambria Capital Investor Meeting in Salt Lake City on March 27, 2008 at 4:00 p.m. MDT.

Isaac Cohen, O.M.D., Chairman and CEO, and Mary Tagliaferri, M.D., President and CMO are both scheduled to present, along with Tom Chesterman, SVP and CFO. The purpose of the presentation will be to update investors on the current business developments and goals for 2008.

No webcast or archive will be available for this presentation. Those investors wishing to attend should contact Cambria Capital at (877) 224-0477 toll free, (801) 320-9606 main or by email at

About Cambria Capital, LLC

Cambria Capital, LLC ("Cambria") is an investment banking and securities brokerage firm with offices in Salt Lake City, Los Angeles and San Francisco. Cambria's mission is to facilitate the growth and development of promising companies at all stages of development by providing capital and a wide variety of financial advisory services. The financing arranged by Cambria originates from a number of sources, including the firm's principals and Cambria's network of high net-worth individuals and institutional investors. Cambria employs a number of corporate finance structures, including PIPEs (Private Investments in Public Equities), private placements of equity and debt securities and reverse mergers. Cambria is a member of the Financial Industry Regulatory Authority, Inc. ("FINRA"), and the Securities Investor Protection Corporation (SIPC). Visit the Cambria website at

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit:

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bionovo Announces Closing of Public Offering of Common Stock
2. Bionovo Describes a New Class of Therapeutic Compounds
3. Bionovo Announces 2007 Financial Results and Highlights
4. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
5. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... “Women have 2 questions when they ... to live?’ The second is, “Will I lose my hair?’” , Carly Klein is ... women with licensed medical professionals to develop personalized hair loss treatment plans. With 10 ...
(Date:10/13/2015)... — , ... ... Association of America (MOAA) will hold its 2015 annual meeting ... a free military career fair; informational seminars; a luncheon featuring ... the Joint Chiefs of Staff; and the Community Heroes Award ...
(Date:10/13/2015)... ... ... The American Institutes for Research ( AIR ) developed a collection of guides ... sexual assault and other trauma. The toolkit, funded by the U.S. Department of Education, ... 21st anniversary. , AIR developed the Safe Place toolkit in ...
(Date:10/13/2015)... ... 13, 2015 , ... "My friend's son suffers from eczema, and he had ... an inventor from Platteville, Colo. "I came up with this kit as a way ... to prevent a child from rubbing or scratching his or her face. This protects ...
(Date:10/13/2015)... , ... October 13, 2015 , ... According to an ... recent study has shown that women who successfully lose weight with a bariatric procedure ... United States each year. The article notes that anywhere from 40 to 50 percent ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 13, 2015  Human Longevity, Inc. (HLI), the genomics-based, ... announced today the launch of the company,s first Health ... the potential to transform healthcare. The inaugural Health Nucleus ... , at HLI,s headquarters facility. More Health Nucleus facilities ... and International cities. --> ...
(Date:10/13/2015)... -- Synapse Biomedical Inc. ( ) reported today that ... use of the NeuRx ® Diaphragm Pacing System ... the United States and patient ... PAS study group met their initial enrollment goal ahead ... expanded the enrollment target to 150 participants.   ...
(Date:10/13/2015)... , Oct. 13 2015 ... addition of the "US & European ... Countries (2010-2021)" report to their offering. ... the addition of the "US & ... 16 Countries (2010-2021)" report to their ...
Breaking Medicine Technology: